Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

• Main Authors: Lorenz von Seidlein (Author), Borimas Hanboonkunupakarn (Author), Podjanee Jittamala (Author), Pongphaya Pongsuwan (Author), Kesinee Chotivanich (Author), Joel Tarning (Author), Richard M. Hoglund (Author), Markus Winterberg (Author), Mavuto Mukaka (Author), Pimnara Peerawaranun (Author), Pasathorn Sirithiranont (Author), Zoe Doran (Author), Christian F. Ockenhouse (Author), Karen Ivinson (Author), Cynthia Lee (Author), Ashley J. Birkett (Author), David C. Kaslow (Author), Pratap Singhasivanon (Author), Nicholas P.J. Day (Author), Arjen M. Dondorp (Author), Nicholas J. White (Author), Sasithon Pukrittayakamee (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,S/AS01 vaccination to the integrated malaria...